A preliminary in vitro and in vivo (C57BL/6 mice) study using DT390mIL-3 (DT390 fused to mouse interleukin 3) confirmed the potential for application of IL-3 to target AML (Chan et al., 1996). The gene discussed is IL3; the disease is acute myeloid leukemia.